Mesoblast Limited (ASX: MSB; Nasdaq: MESO) has highlighted the successful commercial launch of its flagship therapy, Ryoncil® (remestemcel-L-rknd), at two major global healthcare conferences — Morgan Stanley and Cantor Fitzgerald’s Annual Global Healthcare events in New York. This milestone underscores Mesoblast’s position as a global leader in allogeneic cellular medicines for inflammatory diseases.